Retatrutide is an experimental drug from Eli Lilly classified as a triple G agonist targeting GLP-1, GIP, and glucagon receptors for obesity treatment.

How does retatrutide compare to tirzepatide?

Retatrutide targets an additional receptor (glucagon) which may enhance weight loss efficacy but could also lead to more side effects compared to tirzepatide.

What are the potential side effects of retatrutide?

Potential side effects include nausea, vomiting, and diarrhea, common in GLP-1 agonists, but the triple agonist may exacerbate these.

When might retatrutide receive regulatory approval?

Eli Lilly has not yet announced a timeline for regulatory submission, but it is expected to submit Phase 3 data to regulators in the near future.

Lilly's Retatrutide Shows Strong Phase 3 Weight Loss, but Tolerability Concerns Linger

Eli Lilly (LLY) reported positive Phase 3 results for its experimental triple G agonist retatrutide for weight loss, which may offer the best efficacy to date. However, analysts expressed concerns about its tolerability compared to best-seller tirzepatide.

Eli Lilly (NYSE: LLY) announced positive results from a Phase 3 trial of its experimental drug retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors (triple G agonist) for obesity. The drug showed significant weight loss efficacy, potentially the best in its class so far, but analysts have raised concerns about its tolerability profile compared to blockbuster tirzepatide.

Trial Results

The data indicated that retatrutide achieved notable weight reduction in participants, surpassing results seen with tirzepatide in prior trials. However, the company has not yet disclosed exact weight loss percentages or adverse event rates.

Tolerability Concerns

Analysts noted that adverse events (AEs) associated with retatrutide may be more severe than those of tirzepatide, potentially affecting patient compliance. Common side effects of GLP-1 agonists include nausea, vomiting, and diarrhea, but the triple agonist may amplify these effects.

Comparison with Tirzepatide

Tirzepatide (marketed as Mounjaro for diabetes and Zepbound for weight loss) is currently the best-selling drug in the GLP-1 class. Retatrutide targets an additional receptor (glucagon), which may enhance weight loss efficacy but also increase the likelihood of side effects.

Potential Impact on Eli Lilly

If retatrutide gains regulatory approval, it could represent a significant growth opportunity for Eli Lilly, especially if it demonstrates superior efficacy with acceptable tolerability. However, tolerability concerns may limit adoption by physicians and patients.

What This Means for Investors

Investors should monitor full safety data from the trial, as well as the company's plans for regulatory submission. Competition in the obesity drug market is intensifying with new entrants, but Eli Lilly remains well-positioned with its portfolio.